EUVIMEDEUVIMED entdecken
Crossref

Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B

Gerrit Wilms, Kevin Schofield, Shayna Maddern, Christopher Foley iD, Yeng Shaw, Breland Smith, L Emilia Basantes, Katharina Schwandt iD, Aaron Babendreyer, Timothy Chavez, Nicholas McKee, Vijay Gokhale und 7 weitere

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c01130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Gerrit Wilms und 18 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology and Toxicology, RWTH Aachen University, Wendlingweg 2, 52074 Aachen, Germany. Hauptthemen laut MEDLINE: Dyrk Kinases, Protein Serine-Threonine Kinases, Protein-Tyrosine Kinases, Proteolysis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 82 Literaturangaben. Gefördert von: NIA NIH HHS, National Institute of Neurological Disorders and Stroke, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small-molecule-induced protein degradation has emerged as a promising pharmacological modality for inactivating disease-relevant protein kinases. DYRK1A and DYRK1B are closely related protein kinases that are involved in pathological processes such as neurodegeneration, cancer development, and adaptive immune homeostasis. Herein, we report the development of the first DYRK1 proteolysis targeting chimeras (PROTACs) that combine a new ATP-competitive DYRK1 inhibitor with ligands for the E3 ubiquitin ligase component cereblon (CRBN) to induce ubiquitination and subsequent proteasomal degradation of DYRK1A and DYRK1B. The lead compound (DYR684) promoted fast, efficient, potent, and selective degradation of DYRK1A in cell-based assays. Interestingly, an enzymatically inactive splicing variant of DYRK1B (p65) resisted degradation. Compared to competitive kinase inhibition, targeted degradation of DYRK1 by DYR684 provided improved suppression of downstream signaling. Collectively, our results identify DYRKs as viable targets for PROTAC-mediated degradation and qualify DYR684 as a useful chemical probe for DYRK1A and DYRK1B.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dyrk KinasesProtein Serine-Threonine KinasesProtein-Tyrosine KinasesProteolysisProtein Kinase InhibitorsUbiquitin-Protein LigasesHumansAdaptor Proteins, Signal TransducingHEK293 CellsDrug DiscoveryStructure-Activity RelationshipUbiquitination

Substanzen

Dyrk KinasesProtein Serine-Threonine KinasesProtein-Tyrosine KinasesProtein Kinase InhibitorsUbiquitin-Protein LigasesAdaptor Proteins, Signal TransducingCRBN protein, human

Autor:innen und Institutionen

  • Institute of Pharmacology and Toxicology, RWTH Aachen University, Wendlingweg 2, 52074 Aachen, Germany.
  • Division of Drug Discovery and Development, Department of Pharmacology and Toxicology, College of Pharmacy The University of Arizona, Tucson, Arizona 85721, United States.
  • Department of Chemistry and Biochemistry, The University of Arizona, Tucson, Arizona 85721, United States.
  • Institute of Molecular Pharmacology, RWTH Aachen University, Aachen 52074, Germany.
  • BIO5 Institute, The University of Arizona, Tucson, Arizona 85721, United States.
  • Core Facility Translational Proteomics, Institute of Innate Immunity, University Hospital Bonn, Bonn 53127, Germany.

ORCID-Profile: Christopher Foley, Katharina Schwandt, William R Montfort, Walter Becker, Christopher Hulme

Förderung

  • NIA NIH HHS
  • National Institute of Neurological Disorders and Stroke
  • Deutsche Forschungsgemeinschaft
  • National Institute on Aging

Zitieren

APA

Wilms, G., Schofield, K., Maddern, S., Foley, C., Shaw, Y., Smith, B., Basantes, L. E., Schwandt, K., Babendreyer, A., Chavez, T., McKee, N., Gokhale, V., Kallabis, S., Meissner, F., Rokey, S. N., Dunckley, T., Montfort, W. R., Becker, W., & Hulme, C. (2024). Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01130

Vancouver

Wilms G, Schofield K, Maddern S, Foley C, Shaw Y, Smith B, et al. Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01130

BibTeX
@article{Wilms2024,
  author = {Wilms, Gerrit and Schofield, Kevin and Maddern, Shayna and Foley, Christopher and Shaw, Yeng and Smith, Breland and Basantes, L Emilia and Schwandt, Katharina and Babendreyer, Aaron and Chavez, Timothy and McKee, Nicholas and Gokhale, Vijay and Kallabis, Sebastian and Meissner, Felix and Rokey, Samantha N and Dunckley, Travis and Montfort, William R and Becker, Walter and Hulme, Christopher},
  title = {Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c01130}
}
Kostenlos starten →